COVID-19 trials registries data warehouse

http://en.irct.ir/trial/54315

Iraj Ghadiminejad

iraj@gnpau.com

2021-10-23

Completed

RCT

Randomized

Parallel

Blind label

single-center

Treatment

Informed and voluntary oral and written consent of the patient or his / her guardian to participate in the study Age over 18 years SARS-CoV-2 virus PCR test positive or having one of the following conditions: Strong symptoms of COVID-19 disease, including fever, dry cough, and shortness of breath Existence of CT scan confirming lung involvement, especially ground glass view

Individuals whose Covid-19 test has not been approved Individuals who use drugs Individuals who drink alcohol Individuals who use immunosuppressive drugs Individuals under chemotherapy or radiotherapy Individuals who use growth hormone, testosterone and anabolic steroids

2

Ghadiminezhad Daru

18

100

Iran

Moderate disease at enrollment

3: Moderate disease at enrollment

200

Complete Blood Count (CBC), Differentiation Erythrocyte sedimentation rate (ESR) C-Reactive Protein (CRP) Alanine Aminotransferease (ALT) Aspartate aminotransferase (AST) Creatinine Di-Dimer Test Respiratory Presentations Weakness and lethargy Fever Myalgia Dry Cough Existence of sputum Sore throat Diarrhea Shortness of breath Rhinitis Nausea Headache Shivering Presence of ground-glass appearance Alveolar Complication Unilateral or bilateral pulmonary involvement Location of Involvement Presence of Acute respiratory distress syndrome (ARDS)

Phase 3

[{"arm_notes": "", "treatment_id": 2005, "treatment_name": "Endor", "treatment_type": "Vitamins and dietary supplements", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]